Rui Liu | Tumor Radiobiology | Best Researcher Award

Posted on by Pencis

Dr. Rui Liu | Tumor Radiobiology | Best Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

SCOPUS ID

GOOGLE SCHOLAR

🏥DR. RUI LIU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Rui Liu began her academic journey with a strong foundation in biomedical sciences, eventually earning a Ph.D. from a prestigious institution renowned for excellence in public health and molecular oncology. Her early research experiences centered on cellular biology and radiation mechanisms, which laid the groundwork for her specialization in tumor radiobiology and DNA damage repair (DDR).

🩺PROFESSIONAL ENDEAVORS

Currently serving as a Lecturer at the School of Public Health, Wenzhou Medical University, Dr. Liu has dedicated herself to cutting-edge cancer research. With over five years of hands-on laboratory experience, she has developed deep expertise in molecular biology, gene editing (CRISPR-Cas9), animal modeling, bioinformatics, and cellular imaging technologies. Her academic career reflects a balance between rigorous research and impactful teaching, mentoring the next generation of oncology researchers.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR RADIOBIOLOGY

Dr. Liu’s core research explores the molecular intricacies of radiotherapy resistance, with a focus on DNA damage repair pathways and ferroptosis in tumor cells. She has pioneered studies that unravel how long non-coding RNAs (lncRNAs) like MALAT1 influence cancer cell radiosensitivity, potentially leading to enhanced radiotherapy strategies. Her work contributes valuable insights into overcoming therapeutic resistance in breast cancer and other solid tumors.

🌍IMPACT AND INFLUENCE

Dr. Liu’s research has significantly advanced understanding in her field, evidenced by 445+ citations, an H-index of 12, and impactful publications in SCI-indexed journals. She is an active voice in the scientific community, engaging in collaborative research with Jilin University and contributing to national and provincial projects. Her affiliations with professional societies amplify her influence in radiological toxicology and environmental biophysics.

🏆 ACCOLADES AND RECOGNITION

Notable Awards:

  • 🎓 National Scholarship for Doctoral Excellence

  • 🌟 Recognition as a promising young investigator in radiobiology

🏆LEGACY AND FUTURE CONTRIBUTIONS

As an emerging leader in radiation oncology research, Dr. Liu aims to translate molecular findings into clinical applications that improve therapeutic outcomes. She mentors student researchers and continues to expand her interdisciplinary work on novel radiotherapy biomarkers, synthetic lethality, and non-coding RNA therapeutics. Her commitment ensures sustained contributions to precision oncology and translational cancer science.

🧬CONCLUSION

Dr. Rui Liu exemplifies the next generation of scientists transforming cancer treatment through molecular radiobiology. With a robust publication record, interdisciplinary collaborations, and active academic service, she is poised to leave a lasting impact on oncology research, education, and clinical innovation. Her ongoing efforts promise to redefine therapeutic strategies for radiation-resistant cancers.

📊🔬NOTABLE PUBLICATION:

Title: Metal ions overloading and cell death
Authors: Y. Lai, F. Gao, R. Ge, R. Liu, S. Ma, X. Liu
Journal: Cell Biology and Toxicology
Year: 2024

Title: Post‐translational modifications of protein in response to ionizing radiation
Authors: X. Liu, R. Liu, Y. Bai, H. Jiang, X. Fu, S. Ma
Journal: Cell Biochemistry and Function
Year: 2020

Title: The comparison of epidemiological characteristics between confirmed and clinically diagnosed cases with COVID-19 during the early epidemic in Wuhan, China
Authors: F. Shi, H. Wen, R. Liu, J. Bai, F. Wang, S. Mubarik, X. Liu, Y. Yu, Q. Hong, J. Cao, …
Journal: Global Health Research and Policy
Year: 2021

Title: Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population
Authors: R. Liu, L. Ning, X. Liu, H. Zhang, Y. Yu, S. Zhang, W. Rao, J. Shi, H. Sun, Q. Yu
Journal: Oncotarget
Year: 2017

Title: The challenges of precision radiotherapy technology to the traditional theory of radiobiology
Authors: S. Ma, Z. Liang, Q. Chen, R. Liu, Y. Guo, X. Liu
Journal: Chinese Journal of Radiological Medicine and Protection
Year: 2019

Title: Tumor-associated macrophages in radiotherapy: Mechanisms of polarization, immune regulation and therapeutic strategies
Authors: S. Ma, Z. Liang, X. Liu, R. Liu
Journal: Frontiers in Oncology
Year: 2023

Xinglu Jiang | Drug Delivery | Best Researcher Award

Posted on by Pencis

Assoc. Prof. Dr. Xinglu Jiang | Drug Delivery | Best Researcher Award

Guangxi Medical University College | China

AUTHOR PROFILE

SCOPUS ID

ORCID

🏥DR. XINGLU JIANG: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Jiang Xinglu earned his Doctor of Medicine from the Medical School of Southeast University, one of China’s premier medical institutions. His academic focus was in clinical laboratory diagnostics, and he was awarded for outstanding doctoral dissertation, reflecting early excellence in translational medical research.

🩺PROFESSIONAL ENDEAVORS

Currently serving as Associate Professor and Director of the Experimental Research Department at the School of Stomatology, Guangxi Medical University, Dr. Jiang leads advanced research in biomaterials and oral disease diagnostics. He is also recognized among the Outstanding Talents among Youth of Guangxi, marking him as a key figure in the next generation of Chinese medical scientists.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON DRUG DELIVERY

Dr. Jiang’s core research lies at the intersection of biomaterials, nanotechnology, and oral disease therapy. His major interests include:

  • Intelligent anti-tumor drug delivery systems

  • Antibacterial biomaterials

  • Stimuli-responsive hydrogels and nanocarriers

  • Innovative PCR-based diagnostic techniques

  • Carrier-free multidrug therapy systems

His innovative work in tumor microenvironment-triggered nanomedicine and qPCR amplification correction methods represents significant progress in precision medicine and diagnostics.

🌍IMPACT AND INFLUENCE

Dr. Jiang’s research has contributed to:

  • The development of visual antimicrobial hydrogels with regenerative capacity in dental therapy.

  • Advanced PCR technologies for accurate genetic quantification.

  • Carrier-free nanodrug systems for trimodal therapy, combining chemo, photothermal, and starvation treatments for cancer.

These contributions have clinical translational potential in both oncology and dental medicine, influencing practice and technology development in China and internationally.

🏆 ACADEMIC CITES, ACCOLADES AND RECOGNITION

  • Nearly 30 SCI-indexed publications, with over 10 as first or corresponding author.

  • Published in top-tier journals including:

    • ACS Nano

    • Analytical Chemistry (AC)

    • Chemical Engineering Journal (CEJ)

    • Theranostics

    • Journal of Controlled Release (JCR)

    • Analytica Chimica Acta (ACA)

  • Recognized for exceptional publication quality and multidisciplinary innovation.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Jiang is poised to lead next-generation research in:

  • Smart biomaterials for real-time diagnostic feedback

  • Multifunctional nanoplatforms for targeted therapy

  • Standard-free absolute quantification methods in clinical genetics

He is also an advocate for translational research, mentoring emerging scientists and contributing to the future of stomatology and biomedical engineering.

🧬CONCLUSION

Dr. Jiang Xinglu exemplifies the modern medical scientist — innovative, interdisciplinary, and impact-driven. Through cutting-edge contributions in drug delivery systems, oral disease treatment, and clinical diagnostics, he is reshaping the interface between nanomedicine and clinical practice. His trajectory suggests continued breakthroughs, especially in precision therapy and regenerative oral medicine.

📊🔬NOTABLE PUBLICATION:

Sunlight-enhancing the destruction of biomacromolecules caused by Au and Pb ions through cycling between Au(0) and Au(III)

  • Authors: Jiang Xinglu, Qin Yiwu, Zhou Jun, … , Zhou Fengyuan

  • Journal: Colloids and Surfaces A: Physicochemical and Engineering Aspects

  • Year: 2025

Three birds with one stone: a facile superparamagnetic aptasensor for selective capture, dual-mode detection and efficient elimination of methicillin-resistant Staphylococcus aureus

  • Authors: Zhao Fengfeng, Yao Yuming, Ma Shuo, … , Jiang Xinglu, Wu Guoqiu

  • Journal: Chemical Engineering Journal

  • Year: 2025

Visual Antimicrobial Gold Nanocluster Hydrogel with Inflammation-Responsive and Time-Regulated Swelling/Degradation for Regenerative Endodontic Procedures

  • Authors: Xie Beibei, Liang Chunyun, Liu Cong, … , Wang Yaling, Jiang Xinglu

  • Journal: ACS Nano

  • Year: 2025

Ping Dai | Cancer Therapy | Best Researcher Award

Posted on by Pencis

Dr. Ping Dai | Cancer Therapy | Best Researcher Award

Tongji University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. PING DAI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ping Dai’s journey in medicine began with a Diploma of Higher Education in Clinical Medicine from Harbin University, followed by a Bachelor’s degree at Qiqihar Medical University. She excelled further with an Outstanding Master’s Degree in Oncology from Shihezi University, and culminated her academic path with a Doctorate in Molecular Radiation Oncology (Dr. Med, Magna Cum Laude) from the prestigious Heidelberg University in Germany—underscoring a profound commitment to academic excellence and clinical innovation.

🩺PROFESSIONAL ENDEAVORS

With over a decade of clinical and research experience, Dr. Dai currently serves as Assistant Director at the Shanghai Fourth People’s Hospital Affiliated to Tongji University. Her career spans multiple critical roles—oncologist, clinical researcher, and international doctoral candidate at the German Cancer Research Centre (DKFZ)—fusing global perspectives with localized healthcare innovation.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMARKERS  IN CANCER THERAPY

Dr. Dai’s research centers on radiation oncology, immunotherapy-related thyroid dysfunction, and tumor treating fields (TTFields). Notably, her recent studies explore PD-1/PD-L1 inhibitor-induced thyroid dysfunction as a biomarker for efficacy in advanced lung cancer therapy, published in BMC Cancer and Heliyon. She also leads groundbreaking simulation research on electrodynamic tumor interactions, merging clinical oncology with bioengineering insight.

🌍IMPACT AND INFLUENCE

Dr. Dai’s cross-continental experience—from China to Germany—bridges Eastern and Western oncology practices. Her insights contribute to both clinical protocol improvements and space-radiation biology, collaborating with institutions such as the European Space Agency and Heidelberg Ion Beam Therapy Center. She plays a vital role in shaping translational cancer science and space medicine.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

  • Lead or corresponding author in high-impact journals: Cancer Letters (IF 9.7), APL Bioengineering (IF 6.6), and Frontiers in Oncology.

  • Honored with Outstanding Master’s Graduate award.

  • Latin honors “Magna Cum Laude” for doctoral studies in Germany.

  • Recognized as equal-first author and corresponding author in multiple prestigious publications.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Dai is establishing a legacy of translational research at the intersection of radiation therapy, immunology, and biomarker discovery. Her future pursuits aim to:

  • Advance predictive markers for immunotherapy outcomes.

  • Explore MSC-based interventions against radiation-induced myelotoxicity.

  • Lead multinational clinical collaborations in cancer therapy and space radiation countermeasures.

🧬CONCLUSION

Dr. Ping Dai is an emerging force in molecular oncology and translational medicine. With a rich academic foundation, strong clinical acumen, and a forward-thinking research vision, she is contributing impactful solutions to global oncology and radiobiology challenges.

📊🔬NOTABLE PUBLICATION:

Thyroid dysfunction as a predictor of PD-1/PD-L1 inhibitor efficacy in advanced lung cancer

Authors: Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai
Journal: BMC Cancer
Year: 2025

Comprehensive Simulations of Intracellular Electric Fields during Exposure to Tumor Treating Fields (TTFields)

Authors: Kaida Liu, Ping Dai, Zirong Liu, Haohan Fang, Xing Li, Wei Gao
Journal: Frontiers in Oncology
Year: 2025 (Accepted)

Electrodynamic Interaction between Tumor Treating Fields and Microtubule Electrophysiological Activities

Authors: Xing Li, Kaida Liu, Haohan Fang, Zirong Liu, Yuchen Tang, Ping Dai
Journal: APL Bioengineering
Year: 2024

A theoretical study on evaluating brain tumor changes in tumor treating fields therapy by impedance detection

Authors: Xing Li, Kaida Liu, Haohan Fang, Rongzi Liu, Wei Gao, Ping Dai
Journal: Frontiers in Oncology
Year: 2024

Ohidul Alam | Cancer Science | Best Researcher Award

Posted on by Pencis

Dr. Ohidul Alam | Cancer Science | Best Researcher Award

Jiangsu University | China

AUTHOR PROFILE

GOOGLE SCHOLAR

ORCID ID

🏥DR. OHIDUL ALAM: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ohidul Alam began his academic journey with a BSc (Hons.) in Environmental Science at the Institute of Forestry and Environmental Sciences, University of Chittagong, Bangladesh. He further completed his MS in Environmental Science at the same institute. His quest for global academic excellence led him to Tongji University, Shanghai, where he earned his MEng in Environmental Engineering, supported by the UNEP-Tongji Institute of Environment for Sustainable Development. He achieved his Ph.D. in Environmental Engineering from East China University of Science and Technology, focusing on sustainable materials and pollution control.

🩺PROFESSIONAL ENDEAVORS

Dr. Alam’s professional journey is marked by diverse roles across academia, consultancy, and environmental policy. He currently serves as a Post-doctoral Research Fellow at the School of the Environment and Safety Engineering, Jiangsu University, China, where he leads cutting-edge research on heavy metals, microplastics, and hazardous waste management.

Prior roles include:

  • Environmental Officer at the Sustainable Enterprise Project (SEP), Bangladesh

  • Consultant at DM WATCH (focusing on climate change and hazard risk management)

  • Manager at Aurora Consultant Limited

  • Research Assistant for GIZ, IUCN, and Japan-funded environmental and socio-economic projects

  • Guest Lecturer at Chattogram Polytechnic Institute

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON ENVIRONMENT

While Dr. Alam’s primary research is in environmental engineering and waste management, his work has strong implications for cancer science through the lens of public health and environmental carcinogen exposure. His investigation into heavy metals, microplastics, and pollutants directly aligns with cancer risk assessment, particularly regarding chronic exposure to hazardous waste, antibiotic resistance genes, and environmental toxins in water and soil.

His postdoctoral work, titled “Heavy Metals, Microplastics, and Waste Management: Environmental and Health Perspectives”, contributes to the understanding of environmental triggers in non-communicable diseases including cancer.

🌍IMPACT AND INFLUENCE

Dr. Alam has established himself as a globally engaged researcher, presenting in international conferences and contributing to policy-relevant research in South Asia and China. His work informs sustainable practices and evidence-based environmental governance.

  • Participated in leading workshops on Climate Change, LCA, and Solid Waste Management

  • Engaged with international initiatives under UNEP, USAID, and GIZ

  • Actively contributes to academic capacity building in Bangladesh and China

🔑 Keywords: International Collaboration, Environmental Policy, South Asia, Global Sustainability

📚 ACADEMIC CITATIONS, ACCOLADES, AND RECOGNITION

Dr. Alam has published over 31 peer-reviewed journal articles (16 SCI-indexed, 9 open-access international, 3 national journals, and 3 technical notes). Additionally, he has authored 13 international conference papers. He serves as a reviewer for respected journals such as:

  • Journal of Environmental Management

  • Environmental Research

  • Sustainable Cities and Society

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Alam’s research aims to bridge environmental engineering with health and sustainability, particularly focusing on pollution-derived health risks. He envisions developing green materials, safer waste disposal technologies, and cancer risk-reducing environmental frameworks. His mentorship of peers and support for junior researchers highlight his commitment to capacity building and knowledge sharing.

🧬CONCLUSION

Dr. Ohidul Alam stands as a multidisciplinary environmental researcher whose work integrates science, policy, and public health. His academic rigor, international exposure, and dedication to sustainable development make him a formidable contributor to environmental and health sciences, with growing relevance in the domain of environmental oncology and pollution-induced diseases.

📊🔬NOTABLE PUBLICATION:

Influences of chemically controlled Ca-bearing minerals in chitosan on Pb²⁺ removal efficiency

Author(s): Ohidul Alam, Xiuchen Qiao
Journal: Journal of Environmental Health Science and Engineering
Year: 2020

The effect of Ca-bearing contents in chitosan on Pb²⁺, Cd²⁺ and Cu²⁺ adsorption and its adsorption mechanism

Author(s): Ohidul Alam, Xiuchen Qiao, Tapan Kumar Nath
Journal: Journal of Environmental Health Science and Engineering
Year: 2020

A preliminary life cycle assessment on healthcare waste management in Chittagong City, Bangladesh

Author(s): Ohidul Alam, A. Mosharraf
Journal: International Journal of Environmental Science and Technology
Year: 2020

An in-depth review on municipal solid waste management, treatment and disposal in Bangladesh

Author(s): Ohidul Alam, Xiuchen Qiao
Journal: Sustainable Cities and Society
Year: 2020

Determination of the selected heavy metal and metalloid contents in various types of plastic bags

Author(s): Ohidul Alam, Li Yang, Xu Yanchun
Journal: Journal of Environmental Health Science and Engineering
Year: 2019

Xi Chen | Preimplantation Genetic Testing | Best Researcher Award

Posted on by Pencis

Ms. Xi Chen | Preimplantation Genetic Testing | Best Researcher Award

Peking University Third Hospital | China

AUTHOR PROFILE

SCOPUS ID

🏥MS. XI CHEN: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Ms. Xi Chen embarked on her academic journey at Shandong University, where she earned a Bachelor’s degree in Clinical Medicine, laying a strong foundation in clinical sciences. Her commitment to women’s health and reproductive medicine led her to pursue a Ph.D. in Obstetrics and Gynecology at Peking University, one of China’s premier medical institutions.

🩺PROFESSIONAL ENDEAVORS

Ms. Chen has consistently demonstrated excellence in both academic and clinical settings. As a Licensed Physician in China, she bridges research and clinical application, ensuring her work has tangible impact on patient care. Her academic training has been complemented by significant research experience, especially in the field of reproductive genetics.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON PREIMPLANTATION GENETIC TESTING(PGT)

Ms. Chen’s research primarily explores the genetic etiology of adverse pregnancy outcomes, with a special emphasis on Preimplantation Genetic Testing for Monogenic diseases (PGT-M). Her major contributions include:

  1. Investigation of genetic causes of recurrent fetal anomalies, especially those unexplained by traditional diagnostics.

  2. Application of PGT-M in hereditary tumor syndromes, even in cases without a known family history—enhancing the scope and sensitivity of reproductive genetic screening.

  3. Exploring key gene functions in blastocyst development and implantation, bridging the gap between molecular genetics and clinical reproductive outcomes.

🌍IMPACT AND INFLUENCE

Ms. Chen’s work has contributed to advancing precision reproductive medicine in China and beyond. Her research on using affected embryos or single sperm for linkage analysis in PGT-M has opened new avenues for patients with hereditary tumors lacking family history—setting new standards for ethical and practical approaches in assisted reproduction.

🏆ACCOLADES AND RECOGNITION

  • Outstanding Student Cadre, Peking University

  • National Second-Class Academic Scholarship

  • Outstanding Individual in Summer Social Practice, Peking University

These honors reflect her academic excellence, leadership qualities, and community engagement.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Ms. Chen is poised to become a leading figure in reproductive genetics, particularly in the ethical expansion and technical innovation of PGT-M. Her dedication to unraveling complex genetic causes of adverse pregnancy is expected to revolutionize the early detection and prevention of hereditary diseases.

🧬CONCLUSION

Ms. Xi Chen stands at the forefront of reproductive genetics research. With a rare combination of clinical experience, scientific rigor, and innovative thinking, she continues to shape the future of personalized reproductive healthcare. Her commitment to improving diagnostic and therapeutic outcomes for families affected by genetic disorders is both admirable and impactful.

📊🔬NOTABLE PUBLICATION:

Application of the PGT-M strategy using single sperm and/or affected embryos as probands for linkage analysis in males with hereditary tumor syndromes without family history

  • Authors: Chen X#, Wang Y, Guan S, Yan Z, Zhu X, Kuo Y, Wang N, Zhi X, Lian Y, Huang J, Liu P, Li R, Yan L, Qiao J
  • Journal: Journal of Human Genetics
  • Year: 2023 (Published August 18)

Functional profiling of stage-specific proteome and translational transition across human pre-implantation embryo development at a single-cell resolution

  • Dang Y#, Zhu L#, Yuan P#, Liu Q#, Guo Q, Chen X, Gao S, Liu X, Ji S, Yuan Y, Lian Y, Li R, Yan L*, Wong C*, Qiao J*
  • Journal: Cell Discovery
  • Year: 2023

Advances in studying human gametogenesis and embryonic development in China

  • Authors: Liu Q#, Chen X#, Qiao J
  • Journal: Biology of Reproduction
  • Year: 2022

Gang Liu | Stem Cell Therapy | Best Researcher Award

Posted on by Pencis

Prof. Dr. Gang Liu | Stem Cell Therapy | Best Researcher Award

University-Town Hospital of Chongqing Medical University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. GANG LIU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Liu Gang embarked on his medical journey with a strong commitment to excellence in clinical medicine and translational research. After completing his medical degree in China, he pursued postdoctoral training (2008–2010) at the Division of Pulmonary and Critical Care Medicine, Long Island Jewish Medical Center, affiliated with the Albert Einstein College of Medicine in New York, USA. This critical early exposure to international clinical and research environments laid a strong foundation for his future leadership in emergency and critical care medicine.

🩺PROFESSIONAL ENDEAVORS

Dr. Liu currently serves as Chief Physician and Deputy Director at the Department of Emergency Medicine, University Town Hospital, affiliated with Chongqing Medical University. In parallel, he holds a vital administrative role as a Party Committee Member, contributing to strategic hospital governance.

Over the past two decades, Dr. Liu has risen through academic and clinical ranks, now holding titles such as Professor and Chief Physician in Critical Care Medicine, affirming his standing as a national leader in emergency and intensive care services.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON PEDIATRIC CRITICAL CARE MEDICINE

Though Dr. Liu is recognized primarily for his work in adult emergency medicine, his recent research interest has extended into Pediatric Critical Care Medicine, especially in areas intersecting with:

  • Pediatric Sepsis

  • Multi-organ Dysfunction Syndrome (MODS) in Children

  • Early detection and immune modulation in pediatric ICU patients

  • Neonatal emergency protocols during systemic infections

He has led cross-disciplinary initiatives to integrate pediatric-specific protocols into broader critical care workflows, optimizing early recognition and organ support strategies for critically ill pediatric patients in resource-variable settings.

🌍IMPACT AND INFLUENCE

Dr. Liu’s influence reaches national and regional health policy circles, particularly through his roles as:

  • Vice President, Hospital Safety Production Branch, National Association of Health Industry Management

  • Deputy Chair, Security and Protection Committee, Chongqing Hospital Association

Through these positions, he has helped shape emergency care infrastructure, establish hospital safety protocols, and train future critical care leaders, particularly in Western China—a focus of the “Western Region Healthcare Technical Backbone Talent Development Program” he was selected for in 2011.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

Dr. Liu has authored or co-authored numerous peer-reviewed articles, particularly in the domains of sepsis pathophysiology, organ injury, and critical care systems management. His academic work has been:

  • Cited over 1,000 times, reflecting robust clinical relevance and research translation.

  • Recognized in both Chinese national journals and international platforms, particularly for contributions to sepsis immunopathology and ICU systems optimization.

He was also selected for advanced ICU training at Peking University People’s Hospital, one of China’s leading tertiary institutions.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Liu is actively mentoring the next generation of emergency physicians and critical care researchers. He is involved in:

  • Designing pediatric emergency simulation training programs

  • Publishing ICU practice manuals that are being adopted in Chongqing province and beyond

  • Leading multi-center trials on pediatric sepsis resuscitation protocols

His long-term goal is to bridge the gap between adult and pediatric critical care, creating holistic emergency care ecosystems in resource-limited settings.

🧬CONCLUSION

Dr. Liu Gang, MD is a visionary leader in China’s critical and emergency medicine landscape, with a growing footprint in Pediatric Critical Care Medicine. His integrative approach, combining clinical excellence, hospital management, and research acumen, positions him as a catalyst for transformative healthcare solutions in both adult and pediatric critical care.

📊🔬NOTABLE PUBLICATION:

VNS facilitates the neurological function recovery after ischemia/reperfusion injury by regulating the A1/A2 polarization of astrocytes through the NMU-NMUR2 pathway

Authors: X. Jiang, Wendi Yang, Gang Liu, Changqing Li, Sheng Li

Journal: Neurochemistry International

Year: 2025

Xinli Shi | Tumor | Best Researcher Award

Posted on by Pencis

Ms. Xinli Shi | Tumor | Best Researcher Award

Shanxi University of Chinese Medicine | China

AUTHOR PROFILE

SCOPUS ID

ORCID ID

🏥MS. XINLI SHI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Ms. Xinli Shi, a Chinese national, began her academic journey with a B.Sc. in Biochemistry from the Department of Bioengineering at Hebei University of Science and Technology (1996–2001). She deepened her expertise in immunological mechanisms with an M.Sc. in Medical Immunology (2003–2007) from Hebei Medical University, followed by a Ph.D. in Immunology (2011–2014) from the West China College of Basic Medicine and Forensic Medicine, Sichuan University—one of China’s top-tier medical schools.

🩺PROFESSIONAL ENDEAVORS

Prof. Shi’s academic career spans over two decades, reflecting progressive growth:

  • 2001–2013: She served at Hebei Medical University as a Teaching Assistant and then Lecturer, establishing foundational teaching experience.

  • 2013–2018: Appointed Associate Professor and Master’s Supervisor at the School of Basic Medicine, Hebei University of Chinese Medicine.

  • 2015–2017: Completed a Postdoctoral Fellowship at the Bethune International Peace Hospital, affiliated with the Third Military Medical University, focusing on advanced clinical research.

  • 2018–2023: Promoted to Professor and Doctoral Supervisor at Hebei University of Chinese Medicine.

  • 2023–Present: Serving as Professor and Doctoral/Master Supervisor at the Experimental Management Center, Shanxi University of Chinese Medicine.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Prof. Shi has made notable contributions in the field of tumor immunology, particularly within the tumor microenvironment, focusing on:

  • Autophagy

  • Drug Resistance

  • Restenosis

  • Inflammation-induced tumorigenesis

Her research explores how immune signaling and cellular stress responses shape tumor progression and therapeutic resistance, offering novel targets for immunomodulatory and chemotherapeutic interventions.

She has guided:

  • 3 Ph.D. students

  • 20+ M.D. students

  • Supervised postdoctoral fellows, actively fostering academic development and translational medicine research.

🌍IMPACT AND INFLUENCE

Prof. Shi’s work is highly regarded in both Western medicine and Traditional Chinese Medicine (TCM) circles. Her interdisciplinary approach integrates modern immunology with TCM principles, enabling translational applications in cancer and chronic disease therapy. She has been part of numerous provincial and national talent programs, contributing to science policy and medical education reform.

🏆RESEARCH GRANTS AND FUNDING

Prof. Shi has led 14 research projects, funded by prestigious national and provincial bodies. These include:

  • 2 National Natural Science Foundation of China (NSFC) grants (No. 81873112 & 82274315)

  • China Postdoctoral Science Foundation

  • Hebei Natural Science Foundation (multiple years)

  • Shanxi Science and Technology Department

  • Shanxi Provincial Administration of Traditional Chinese Medicine Innovation Team

🔹 Total grant portfolio spans over a decade, supporting basic, translational, and clinical research initiatives.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Prof. Shi’s career exemplifies academic excellence, clinical relevance, and mentorship. With growing involvement in Shanxi’s TCM innovation programs, she is positioned to pioneer integrative oncology in China—blending evidence-based traditional practices with cutting-edge immunotherapy research. Her future directions include:

  • Building innovation teams

  • Leading multi-center translational studies

  • Expanding doctoral and postdoctoral programs

  • Enhancing international collaborations in cancer research

🧬CONCLUSION

Prof. Xinli Shi stands at the confluence of biochemistry, medical immunology, and TCM oncology, with over 20 years of academic and clinical experience. Her dedication to tumor biology, immune modulation, and interdisciplinary research continues to shape the landscape of cancer therapeutics in China. As a mentor, scholar, and innovator, she contributes profoundly to the development of next-generation scientists and the advancement of personalized medicine.

📊🔬NOTABLE PUBLICATION:

RalB promotes lymph node metastasis in tongue squamous cell carcinoma

Authors: Y. Zhang, Yuman; Z. Liu, Zhihan; Y. Yang, Yanguang; L. Jia, Lifeng; X. Shi, Xinli
Journal: Genes and Genomics
Year: 2025

Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma

Authors: Y. Yang, Yanguang; S. Li, Shenghao; Q. Peng, Qing; Y. Zhang, Yuman; X. Shi, Xinli
Journal: Molecular Biology Reports
Year: 2024

Recent advances in graphitic carbon nitride-based heterojunction for biomedical applications

Authors: R. Jia, Ruilong; C. He, Cheng’en; S. Wang, Shanshan; G. Liao, Guangfu; X. Shi, Xinli
Citations: 3

Zhichen Xu | Radiation Oncology | Best Researcher Award

Posted on by Pencis

Zhichen Xu | Radiation Oncology | Best Researcher Award

First Hospital of Quanzhou | China

AUTHOR PROFILE

SCOPUS ID

🏥MR. ZHICHEN XU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Mr. Xu Zhichen, originally from Putian and a member of the Han ethnic group, embarked on his medical journey at Luzhou Medical College, where he earned his Bachelor’s degree in Clinical Neurology (2005–2010). Driven by a growing interest in cancer care, he pursued a Master’s degree in Radiation Oncology at Fujian Medical University (2010–2013). His postgraduate training, conducted at the Fujian Provincial Tumor Hospital, laid the foundation for his specialization in radiotherapy.

🩺PROFESSIONAL ENDEAVORS

After completing his academic training, Mr. Xu underwent standardized residency training at Quanzhou First Hospital (2013.9–2014.9). Since September 2014, he has been an integral part of the hospital’s Radiotherapy Department, where he applies advanced radiotherapeutic techniques in clinical oncology. In 2024, he achieved the Vice Senior Certification in Radiotherapy, a testament to his professional growth and clinical mastery over the past decade.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON RADIATION ONCOLOGY

Mr. Xu specializes in Radiation Oncology, with a particular emphasis on esophageal cancer, focusing on enhancing therapeutic efficacy and patient outcomes. His clinical efforts are complemented by a strong commitment to research in radiotherapy optimization, side effect mitigation, and individualized treatment approaches.

🌍IMPACT AND INFLUENCE

A rising leader in regional cancer care, Mr. Xu is a core member of the Youth Committee of the Fujian Radiation Oncology Society. His selection for the “Hundred Talent Program” at Quanzhou First Hospital underlines his value as a future-forward clinician contributing to institutional development and innovation in cancer treatment.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Mr. Xu Zhichen aims to deepen his impact through work on precision radiotherapy, multidisciplinary cancer management, and the integration of AI and imaging technologies in clinical decision-making. He is committed to mentoring young oncologists and fostering collaborative research within and beyond Quanzhou.

🧬CONCLUSION

Mr. Xu Zhichen exemplifies the ideal blend of clinical expertise, research acumen, and leadership potential in the field of Radiation Oncology. With a focus on esophageal cancer, he continues to shape the future of radiotherapy in Fujian Province while contributing meaningfully to national and international cancer care standards.

 

📊🔬NOTABLE PUBLICATION:

A dynamic nomogram for predicting abdominal lymph node recurrence in patients with esophageal carcinoma

Authors: Xu Zhichen, Su Baoan, Lin Mingqiang, Xu Qinghua, Qu Mengke
Journal: Scientific Reports
Year: 2025

Dong Zhu | Organ-Defined Cancers | Best Researcher Award

Posted on by Pencis

Dong Zhu | Organ-Defined Cancers | Best Researcher Award

临沂大学 | China

AUTHOR PROFILE

SCOPUS ID

🏥MR. DONG ZHU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Born in May 1999 in Zaozhuang, Shandong Province, China, Mr. Zhu Dong displayed an early aptitude for analytical thinking and computing. He embarked on his academic journey at Linyi University, earning a Bachelor of Engineering in Computer Science and Technology (2020–2022). Recognized for his diligence and academic excellence, he was admitted into the university’s graduate program, where he is currently pursuing a Master of Engineering in Computer Technology (2022–2025).

🩺PROFESSIONAL ENDEAVORS

While still a graduate student, Mr. Zhu has already made substantial strides in the field of medical image processing. He has co-developed advanced deep learning frameworks tailored to complex clinical imaging tasks, such as 3D liver segmentation and breast tumor analysis. His participation in collaborative and interdisciplinary projects reflects a forward-looking and adaptable research mindset.

🔬CONTRIBUTIONS AND RESEARCH FOCUS

Mr. Zhu’s primary research focus is on deep learning applications in medical image segmentation, with specific interests in:

  • 3D U-Net architectures
  • Attention mechanisms
  • Multi-scale feature fusion
  • Electrocardiogram (ECG) signal classification

🏆AWARDS AND HONOURS

  • National Scholarship, 2023–2024
  • First-Class Academic Scholarship, 2022–2023 & 2023–2024
  • Outstanding Communist Youth League Cadre, 2023–2024
  • Excellent Student Award, 2023–2024
  • Advanced Individual Award, 2023–2024

🌍IMPACT AND INFLUENCE

Though early in his career, Mr. Zhu’s models are contributing to more accurate, automated diagnosis systems in clinical imaging. His open-access publications and conference proceedings are cited in discussions around deep learning for medical applications, particularly in liver and breast imaging workflows. His interdisciplinary work is fostering stronger links between AI and clinical diagnostics.

🏆LEGACY AND FUTURE CONTRIBUTIONS

With a growing portfolio of first-author publications, Mr. Zhu is establishing himself as a rising researcher in AI-driven medical imaging. His focus on practical, clinically relevant problems positions him to contribute significantly to next-generation diagnostic technologies. In the coming years, he aims to expand his research to include multimodal imaging analysis, federated learning, and real-time diagnostic systems for point-of-care settings.

🧬CONCLUSION

Mr. Zhu Dong represents a new wave of interdisciplinary researchers who blend deep learning techniques with clinical needs. His trajectory reflects not only strong technical skills but also a deep commitment to improving healthcare through innovation. With continued support, mentorship, and exposure to global research networks, he is well-poised to lead breakthroughs in intelligent medical diagnostics.

 

📊🔬NOTABLE PUBLICATION:

3DMAU-Net: Liver Segmentation Network Based on 3D U-Net

Authors: Zhu, Dong; Ma, Tianyi; Yang, Mengzhu; Hu, Shunbo; Wang, Yongfang
Journal: Optoelectronics Letters
Year: 2025

Haixin Liang | Oncology Nursing | Best Researcher Award

Posted on by Pencis

Ms. Haixin Liang | Oncology Nursing | Best Researcher Award

Sichuan Cancer Hospital | China

AUTHOR PROFILE

ORCID ID

🎓 EARLY ACADEMIC PURSUITS

Born in April 1987 in China, Haixin Liang embarked on her journey in healthcare with a deep commitment to service and academic excellence. She earned her Master’s degree in Nursing, laying the foundation for a focused career in oncology nursing. Her early academic training fostered a keen interest in clinical innovation, evidence-based care, and nursing education.

🏆 PROFESSIONAL ENDEAVORS

Since July 2012, Liang has served at Sichuan Cancer Hospital, one of China’s leading institutions in cancer treatment and research. Currently holding the position of Nurse Supervisor and Oncology Advanced Practice Nurse, she plays a pivotal role in patient care management, nursing staff training, and clinical innovation. Liang’s responsibilities span clinical supervision, implementation of best nursing practices, and mentoring student nurses.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY NURSING

Haixin Liang’s professional contributions are deeply rooted in the nursing care of oncology patients, particularly focusing on:

  • Radiation-induced complications

  • Patient-centered safety practices

  • Clinical device innovations for cancer care

Her research often emphasizes the quality of life of nasopharyngeal carcinoma patients, symptom management, and infection control.

🌍 IMPACT AND INFLUENCE

Liang’s innovations and scholarly work have had a direct impact on clinical practice, particularly in:

  • Infection control through safe disposal of medical sharps

  • Improved nursing techniques in managing radiation-induced complications

  • Enhancing communication and understanding between caregivers and patients

Her educational leadership has influenced the next generation of oncology nurses, while her research is integrated into hospital protocols and academic curricula.

.

📖 ACADEMIC CITATIONS AND RECOGNITION

While specific citation data is not provided here, her frequent first-author contributions in core Chinese nursing journals suggest substantial academic recognition and relevance in the field of clinical nursing innovation, especially among oncology nursing practitioners in China.

🔮RESEARCH GRANTS AND FUNDING

Liang’s device innovations have led to two awarded patents, indicating support for clinical translation of nursing tools:

  • 🧪 Portable Sharps Disposal Container
    Patent Number: ZL 2014 20067555.3 – Issued: 2014.08.06

  • 🧪 Nasogastric Tube Injection Device
    Patent Number: ZL 2020 22568964.X – Issued: 2020.11.09

Her work is further supported through institutional awards and case competitions, signifying recognition and potential for funding in applied clinical research.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Haixin Liang’s legacy lies in:

  • Bridging practical nursing with innovation

  • Leading in radiotherapy nursing care

  • Cultivating student and staff excellence in oncology nursing

Her future contributions are expected to include:

  • Development of more patient-friendly clinical devices

  • Publishing guidelines for managing radiotherapy side effects

  • Expanding evidence-based nursing frameworks in oncology

🌍CONCLUSION 

Haixin Liang exemplifies a nurse leader who transcends bedside care through innovation, research, and mentorship. With a focused commitment to oncology nursing, her work continues to shape clinical practices and empower nursing professionals across China. Her profile is a testament to how clinical insight, scholarly pursuit, and technological innovation can converge in nursing for maximum patient impact.

 

📊🔬NOTABLE PUBLICATION:

Correlation between changes of taste or smell and self-reported symptoms in patients with nasopharyngeal carcinoma received radiotherapy and chemotherapy

Authors: Haixin Liang (First Author)

Journal: Guangdong Medical Journal

Year: 2018